Sökning: WFRF:(Roche Nicolas) >
Indacaterol/glycopy...
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD : FLAME-based modelling in a Swedish population
-
- Bjermer, Leif (författare)
- Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Lund Univ, Skåne Univ Hosp, Dept Resp Med & Allergol, Lund
-
- van Boven, Job F.M. (författare)
- University Medical Center Groningen,University of Groningen,Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma, Dept Gen Practice, Groningen, Netherlands.;Univ Groningen, Univ Med Ctr Groningen, COPD GRIAC, Groningen, Netherlands.;Univ Groningen, Dept Pharm, Unit Pharmacoepidemiol & Pharmacoecon, Groningen
-
- Costa-Scharplatz, Madlaina (författare)
- Novartis Sverige AB, Täby
-
visa fler...
-
- Keininger, Dorothy L. (författare)
- Novartis Pharma AG, Basel
-
- Gutzwiller, Florian S. (författare)
- Novartis Pharma AG, Basel
-
- Lisspers, Karin, Docent, 1954- (författare)
- Uppsala universitet,Uppsala University,Allmänmedicin och preventivmedicin
-
- Mahon, Ronan (författare)
- Novartis Ireland Limited,Novartis Ireland Ltd, Dublin
-
- Olsson, Petter (författare)
- Novartis Sverige AB, Täby
-
- Roche, Nicolas (författare)
- Paris Descartes University,Cochin Hosp, AP HP, Resp & Intens Care Med, Paris, France.;Univ Paris 05, Paris
-
visa färre...
-
(creator_code:org_t)
- 2017-12-11
- 2017
- Engelska.
-
Ingår i: Respiratory Research. - : Springer Science and Business Media LLC. - 1465-9921 .- 1465-993X. ; 18:1
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://respiratory-...
-
https://doi.org/10.1...
-
https://uu.diva-port... (primary) (Raw object)
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. Methods: A previously published and validated patient-level simulation model was adapted using clinical data from the FLAME trial and real-world cost data from the ARCTIC study. Costs (total monetary costs comprising drug, maintenance, exacerbation, and pneumonia costs) and health outcomes (life-years (LYs), quality-adjusted life-years (QALYs)) were projected over various time horizons (1, 5, 10 years, and lifetime) from the Swedish payer's perspective and were discounted at 3% annually. Uncertainty in model input values was studied through one-way and probabilistic sensitivity analyses. Subgroup analyses were also performed. Results: IND/GLY was associated with lower costs and better outcomes compared with SFC over all the analysed time horizons. Use of IND/GLY resulted in additional 0.192 LYs and 0.134 QALYs with cost savings of €1211 compared with SFC over lifetime. The net monetary benefit (NMB) was estimated to be €8560 based on a willingness-to-pay threshold of €55,000/QALY. The NMB was higher in the following subgroups: severe (GOLD 3), high risk and more symptoms (GOLD D), females, and current smokers. Conclusion: IND/GLY is a cost-effective treatment compared with SFC in COPD patients with mMRC dyspnea grade ≥ 2, moderate to very severe airflow limitation, and ≥1 exacerbation in the preceding year.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Nyckelord
- Chronic obstructive pulmonary disease
- Cost-effective
- Exacerbation
- Indacaterol/glycopyrronium
- Chronic obstructive pulmonary disease
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas